Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailGlial but not neuronal development in the cochleo-vestibular ganglion requires Sox10.
Breuskin, Ingrid ULg; Bodson, Morgan ULg; Thelen, Nicolas ULg et al

in Journal of Neurochemistry (2010), 114(6), 1827-39

The cochleo-vestibular ganglion contains neural crest-derived glial cells and sensory neurons that are derived from the neurogenic otic placode. Little is known about the molecular mechanisms that ... [more ▼]

The cochleo-vestibular ganglion contains neural crest-derived glial cells and sensory neurons that are derived from the neurogenic otic placode. Little is known about the molecular mechanisms that regulate the tightly orchestrated development of this structure. Here, we report that Sox10, a high-mobility group DNA-binding domain transcription factor that is required for the proper development of neural crest cell derivatives, is specifically expressed in post-migratory neural crest cells in the cochleo-vestibular ganglion. Using Sox10-deficient mice, we demonstrate that this transcription factor is essential for the survival, but not the generation, of the post-migratory neural crest cells within the inner ear. In the absence of these neural crest-derived cells, we have investigated the survival of the otocyst-derived auditory neurons. Surprisingly, auditory neuron differentiation, sensory target innervation and survival are conserved despite the absence of glial cells. Moreover, brain-derived neurotrophic factor expression is increased in the hair cells of Sox10-deficient mice, a compensatory mechanism that may prevent spiral ganglion neuronal cell death. Taken together, these data suggest that in the absence of neural crest-derived glial cells, an increase trophic support from hair cells promotes the survival of spiral ganglion neurons in Sox10 mutant mice. [less ▲]

Detailed reference viewed: 88 (21 ULg)
Full Text
Peer Reviewed
See detailGlial control of neuronal excitability in mammals: I. Electrophysiological and isotopic evidence in culture.
Moonen, Gustave ULg; FRANCK, G.; SCHOFFENIELS, E.

in Neurochemistry International (1980), 2c

Detailed reference viewed: 9 (0 ULg)
Peer Reviewed
See detailGlial organization in the developing reeler neocortex
Gadisseux, J.-F.; Evrard, Ph; Misson, Jean-Paul ULg et al

in Neuroscience (1988)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailGlial process elongation and branching in the developing murine neocortex: A qualitative and quantitative immunohistochemical analysis
Takahashi, Takao; Misson, Jean-Paul ULg; Caviness, Verne S

in Journal of Comparative Neurology (The) (1990), 302

Detailed reference viewed: 17 (1 ULg)
See detailGLIMMER – Global-Local Information Merging for Maturing Emergency Response
Binon, Kris; Brunet, Sébastien ULg; Cornélis, Bernard et al

Report (2008)

Un guide, d’accord... mais pour quoi faire ? Nous tous sommes quotidiennement exposés à une variété inimaginable de risques. Au niveau individuel, ces risques sont liés à notre constitution personnelle, à ... [more ▼]

Un guide, d’accord... mais pour quoi faire ? Nous tous sommes quotidiennement exposés à une variété inimaginable de risques. Au niveau individuel, ces risques sont liés à notre constitution personnelle, à nos activités, à nos relations sociales, et à nos biens matériels et immatériels. Ce n'est que lorsqu'ils se concrétisent que nous en subissons les effets, par exemple respectivement: allergie, chute à ski, divorce, panne de gsm ou trou de mémoire. À ces risques touchant la sphère privée, s'ajoutent les risques touchant tout ou partie de la société. Ces derniers proviennent soit de la société ellemême ou de ses composantes (e.g. pollution atmosphérique, émeute), soit de l'environnement naturel (e.g. tremblement de terre). 2. Pour les risques concernant la société, les autorités publiques ont mis en oeuvre une série de politiques pour rencontrer les attentes et besoins de la population. En cas de sinistres, l’intervention d’acteurs organisés (services d'incendie, de secours, de police, cellule de crise,...) permet de répondre aux situations d'urgence. De façon à améliorer cette réponse, des plans d'intervention et d'urgence sont établis. Ces plans trouvent leur fondement dans une démarche pro-active: l'analyse de risques. Le nombre des risques étant quasiment infini, il importe d’opérer des choix. Les objectifs de ce guide sont multiples : - aider les acteurs des cellules de sécurité à travailler ensemble; - proposer des moyens permettant d’opérer un choix à bon escient; - contribuer à la prise de décisions rationnelles en matière de planification; - favoriser les échanges entre les autorités territoriales et avec les entreprises privées; - ... 3. La démarche suivie par le projet GLIMMER repose sur l'apprentissage organisationnel. Cela implique d'une part le partage d'expériences, mais aussi de franchir des paliers avec l'ensemble des autorités publiques. Ce manuscrit est l'embryon d'un manuel plus développé. Vu la demande des autorités locales de commencer leur travail d'analyse de risques avec la présente méthode, le comité d'accompagnement a décidé de mettre à leur disposition ce guide qui contient le coeur de la méthode élaborée. Des bribes d'une version ultérieure peuvent donc apparaître de temps à autre dans ce document. 4. Cette première version du guide est divisée en quatre parties principales. La première partie vise à replacer le guide dans un contexte général (celui de la gestion des risques et de la planification) et particulier (celui la mise en place de cellules de sécurité). La deuxième partie a pour objectif de fournir un cadre théorique. Il s’agit principalement de rendre compréhensible des concepts parfois flous, polysémiques ou mal maîtrisés et de constituer un cadre de référence commun. La troisième partie n’a pour autre ambition que de fournir une aide à la mise en place des cellules de sécurité et à leur bon fonctionnement. La quatrième partie est dédiée aux méthodes d'analyse de risques. Enfin, le guide est agrémenté d’annexes dans lesquelles se trouvent outils, renseignements utiles, etc. [less ▲]

Detailed reference viewed: 64 (5 ULg)
See detailA Glimpse from the Imaginaries of a Nanofuture Conference in Leuven, Belgium
Van Oudheusden, Michiel ULg

Article for general public (2007)

Detailed reference viewed: 7 (0 ULg)
See detailGlioblastoma metastases:case report and literature review
REUTER, Gilles ULg; Lombard, Arnaud ULg; SCHOLTES, Félix ULg et al

Poster (2013, March 30)

Detailed reference viewed: 33 (12 ULg)
Full Text
Peer Reviewed
See detailLes glioblastomes, un exemple de recherche translationnelle?
Kroonen, Jérôme ULg; Nguyen-Khac, Minh-Tuan ULg; Deprez, Manuel ULg et al

in Revue Médicale de Liège (2008), 63(5-6), 251-6

Among patients which develop glioblastoma multiform (GBM), recurrence is the rule despite continuous progress in surgery, radiotherapy and chemotherapy. In the adult, GBM is the most frequent and most ... [more ▼]

Among patients which develop glioblastoma multiform (GBM), recurrence is the rule despite continuous progress in surgery, radiotherapy and chemotherapy. In the adult, GBM is the most frequent and most aggressive tumour of the Central Nervous System. A better understanding of the mechanisms by which these tumours relapse could promote the use of preventive therapy and could increase patients' survival. GBM stem cells have been recently described and it was demonstrated that they are specifically implied in the experimental tumorigenesis. It is thus very attractive to speculate on a possible relationship between these GBM stem cells and the neural stem cells which are persisting in the neurogenic zones of the adult brain. In this review, we formulate and discuss the hypothesis by which, in a patient with GBM, malignant stem cells might be present in the neurogenic zones, away from the tumour mass. This hypothesis could explain the tumour relapse observed after the first treatments. [less ▲]

Detailed reference viewed: 146 (49 ULg)
See detailGlioma metastatis : a case series and review
REUTER, Gilles ULg; LOMBARD, Arnaud ULg; SCHOLTES, Félix ULg et al

Poster (2014, March 29)

Detailed reference viewed: 24 (2 ULg)
Peer Reviewed
See detailGliomatose méningée cérébro-spinale diffuse chez un enfant traité par hormone de croissance dans le cadre d!un syndrome de Turner
Dacier, Ph; Leroy, P.; Ernould, Ch et al

in Société Belge de Neurologie Pédiatrique (1995)

Detailed reference viewed: 60 (1 ULg)
Peer Reviewed
See detailGliomatosis Cerebri: Clinical, Radiological and Pathological Report of a Case with a Stroke-Like Onset
Schoenen, Jean ULg; de Leval, L.; Reznik, M.

in Acta Neurologica Belgica (1996), 96(4), 294-300

A 62 year-old man was admitted with a right hemiparesis, sensory aphasia and right hemianopia which appeared on awakening. He was initially thought to have a stroke, but EEG showed diffuse slowing and ... [more ▼]

A 62 year-old man was admitted with a right hemiparesis, sensory aphasia and right hemianopia which appeared on awakening. He was initially thought to have a stroke, but EEG showed diffuse slowing and both CT scan and MRI irregular white matter lesion suggesting a leucoencephalopathy. His neurological deficit regressed, and he was discharged after 2 weeks. He was readmitted 6 months later because of mental confusion. MRI revealed diffuse white matter lesions extending up to the frontal lobes, these were hyperintense on T2 weighted images and suggested the diagnosis of gliomatosis cerebri (GC). The patient became progressively comatose and died 6 weeks later. At autopsy the brain looked diffusely swollen with irregular greyish areas of the white matter of both centrum ovale and brain stem. On microscopic examination the cerebrum and brain stem were diffusely and asymmetrically infiltrated by numerous neoplastic glial cells without angiogenesis or disruption of architectonic boundaries. There were no mitoses nor necrosis. Many tumour cells were GFAP- and S100-positive. A high proportion of cells contained the leucocyte antigen Leu-7. This case of gliomatosis cerebri is compared to the 9 published cases of GC with an initial focal neurological deficit and to the 19 publications reporting MRI results. The controversial nosological boundaries and etiopathogenetic hypotheses of this peculiar neoplastic disease are discussed. [less ▲]

Detailed reference viewed: 29 (2 ULg)
Peer Reviewed
See detailGlipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
Scheen, André ULg; Lefebvre, Pierre ULg; Luyckx, A. S.

in European Journal of Clinical Pharmacology (1984), 26(4), 471-4

Peripheral blood glucose, plasma insulin and C-peptide levels were investigated after giving a standardized breakfast (500 kcal, 60 g carbohydrates) to 10 nonobese Type 2 diabetic patients previously ... [more ▼]

Peripheral blood glucose, plasma insulin and C-peptide levels were investigated after giving a standardized breakfast (500 kcal, 60 g carbohydrates) to 10 nonobese Type 2 diabetic patients previously treated by diet alone. Each patient received at random, at 1 week intervals, either 5 mg glipizide (meal + glipizide) or a placebo (meal alone) 30 min before breakfast. Basal values of blood glucose, plasma insulin and C-peptide were similar on both occasions. After meal + glipizide, the blood glucose increase was sharply limited whereas the rise in plasma insulin was steeper and reached twice as high a level. In contrast, the rise in plasma C-peptide was similar in both conditions. Consequently, the areas under the curves (0-300 min) showed a marked reduction in blood glucose after meal + glipizide (2289 +/- 149 versus 3101 +/- 169 mmol X min/1; 2p less than 0.001), associated with a significant increase in plasma insulin (14219 +/- 3261 versus 7591 +/- 1173 microU X min/ml; 2p less than 0.025) but no significant change in plasma C-peptide (342 +/- 45 versus 326 +/- 34 pmol X min/ml; N.S.). The insulin/C-peptide molar ratio was thus significantly increased after meal + glipizide (0.41 +/- 0.06 versus 0.23 +/- 0.04 at the 60th min; 2p less than 0.02). The dissociation between the responses of insulin and C-peptide suggests that a single dose of 5 mg glipizide in Type 2 diabetic subjects may enhance availability of peripheral insulin by extrapancreatic mechanism(s). This phenomenon may result in a higher circulating level of the hormone and therefore represent a further mode of action of sulphonylureas.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 30 (0 ULg)
Full Text
Peer Reviewed
See detailGliptin versus a sulphonylurea as add-on to metformin.
SCHEEN, André ULg; Paquot, Nicolas ULg

in Lancet (2012), 380

Detailed reference viewed: 37 (5 ULg)
Full Text
Peer Reviewed
See detailLes gliptines, une nouvelle mode?
SCHEEN, André ULg

in Revue du Praticien (La) (2013), 63(3), 304-5

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailGliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
SCHEEN, André ULg

in Expert Opinion on Drug Safety (2013), 12(4), 545-57

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in the management of type 2 diabetes. Such incretin-based therapies offer some advantages over other glucose ... [more ▼]

Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) play an increasing role in the management of type 2 diabetes. Such incretin-based therapies offer some advantages over other glucose-lowering agents, but might be associated with an increased risk of acute pancreatitis. Areas covered: An extensive literature search was performed to analyze clinical cases of acute pancreatitis reported in the literature or to the Food and Drug Administration (FDA), in randomized clinical trials, and in observational studies with five DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. Expert opinion: An increased risk of pancreatitis has been reported in diabetic versus nondiabetic patients. Several anecdotal clinical cases of pancreatitis have been reported with sitagliptin and vildagliptin and an increased relative risk reported to the FDA with sitagliptin versus other comparators, but reporting bias cannot be excluded. In rather short-term clinical trials with well-selected diabetic patients, no increased risk of acute pancreatitis has been observed with any of the five commercialized DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin. Similarly, real-life cohort studies showed no increased incidence of pancreatitis with gliptins compared with other glucose-lowering agents, a finding recently challenged by a case- control study. These results must be confirmed in postmarketing surveillance programs and in ongoing large prospective trials with cardiovascular outcomes. [less ▲]

Detailed reference viewed: 14 (0 ULg)
Full Text
See detailGlissement progressif de l’analyse et de la gestion des risques des autorités publiques aux opérateurs industriels
Brunet, Sébastien ULg; Michel, Quentin ULg

in Revue de la Faculté de Droit de l'Université de Liège (2006), 2006/1-2

Detailed reference viewed: 26 (7 ULg)
Full Text
Peer Reviewed
See detailGlitazones et insuffisance cardiaque: resultats des etudes PROactive, ADOPT, DREAM et RECORD.
De Flines, Jenny ULg; Scheen, André ULg

in Revue Médicale Suisse (2007), 3(122), 18761878-83

Thiazolidinediones (TZDs) are used as insulin sensitizers in the treatment of type 2 diabetes, but are associated with an increased risk of congestive heart failure (CHF). The odds ratio of ICC was 1.43 ... [more ▼]

Thiazolidinediones (TZDs) are used as insulin sensitizers in the treatment of type 2 diabetes, but are associated with an increased risk of congestive heart failure (CHF). The odds ratio of ICC was 1.43 (pioglitazone vs placebo) in diabetic patients with high cardiovascular risk in the PROactive trial while it averaged 1.22 (rosiglitazone vs metformin) and 2.20 (rosiglitazone vs metformin) in the ADOPT study. In the interim analysis of the ongoing RECORD trial, the odds ratio averaged 2.15 (rosiglitazone vs metformin or sulfonylureas). In four real life registries, the relative risk of CHF with TZDs varied between 1.06 and 1.76 (between 1.10 and 1.44 combined with insulin) as compared to a treatment without TZDs. Such higher CHF risk should be appreciated according to the potential benefits of glitazones in the management of type 2 diabetes. [less ▲]

Detailed reference viewed: 51 (0 ULg)
Full Text
Peer Reviewed
See detailGlnR-mediated regulation of nitrogen metabolism in the actinomycete Saccharopolysporaerythraea
Li-Li, Yao; Cheng-Heng, Liao; Gang, Huang et al

in Applied Microbiology and Biotechnology (2014)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailGlobal adaptive stabilization of cascade nonlinear systems
Jankovic, M.; Sepulchre, Rodolphe ULg; Kokotovic, Petar V.

in Automatica (1997), 33(2), 263-368

An adaptive controller is developed for a class of nonlinear systems for which other approaches (e.g. backstepping) may fail to be applicable. The new design employs feedback passivation and an explicit ... [more ▼]

An adaptive controller is developed for a class of nonlinear systems for which other approaches (e.g. backstepping) may fail to be applicable. The new design employs feedback passivation and an explicit construction of a Lyapunov function for the zero dynamics with respect to a relative degree 1 output. As an illustration a longstanding "nonlinear benchmark problem" is solved. [less ▲]

Detailed reference viewed: 12 (1 ULg)